Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engelman

Showing results (171-180 of 238) with videos related to

Pageof 24
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2008
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutationsLecia V Sequist, Renato G Martins, David Spigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancerJussi P Koivunen, Craig Mermel, Kreshnik Zejnullahu, et al.
Cancer Cell|March 12, 2015
A functional landscape of resistance to ALK inhibition in lung cancerFrederick H Wilson, Cory M Johannessen, Federica Piccioni, et al.
Nature Communications|May 28, 2021
Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancerBernard Pereira, Christopher T Chen, Lipika Goyal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2012
Activation of PI3K signaling in Merkel cell carcinomaValentina Nardi, Youngchul Song, Juan A Santamaria-Barria, et al.
The New England Journal of Medicine|March 28, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancerAlice T Shaw, Dong-Wan Kim, Ranee Mehra, et al.
EMBO Molecular Medicine|May 1, 2010
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicineDora Dias-Santagata, Sara Akhavanfard, Serena S David, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2016
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective AnalysisJustin F Gainor, Alice T Shaw, Lecia V Sequist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase SignalingChen Liu, Hengyu Lu, Hongyun Wang, et al.
Science Translational Medicine|March 25, 2011
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsLecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, et al.
Pageof 24

Showing results (171-180 of 238) with videos related to

Sort By:
Pageof 24
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2008
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutationsLecia V Sequist, Renato G Martins, David Spigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 3, 2008
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancerJussi P Koivunen, Craig Mermel, Kreshnik Zejnullahu, et al.
Cancer Cell|March 12, 2015
A functional landscape of resistance to ALK inhibition in lung cancerFrederick H Wilson, Cory M Johannessen, Federica Piccioni, et al.
Nature Communications|May 28, 2021
Cell-free DNA captures tumor heterogeneity and driver alterations in rapid autopsies with pre-treated metastatic cancerBernard Pereira, Christopher T Chen, Lipika Goyal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2012
Activation of PI3K signaling in Merkel cell carcinomaValentina Nardi, Youngchul Song, Juan A Santamaria-Barria, et al.
The New England Journal of Medicine|March 28, 2014
Ceritinib in ALK-rearranged non-small-cell lung cancerAlice T Shaw, Dong-Wan Kim, Ranee Mehra, et al.
EMBO Molecular Medicine|May 1, 2010
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicineDora Dias-Santagata, Sara Akhavanfard, Serena S David, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 27, 2016
EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective AnalysisJustin F Gainor, Alice T Shaw, Lecia V Sequist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2020
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase SignalingChen Liu, Hengyu Lu, Hongyun Wang, et al.
Science Translational Medicine|March 25, 2011
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsLecia V Sequist, Belinda A Waltman, Dora Dias-Santagata, et al.
Pageof 24